Targeting AKT signaling sensitizes cancer to cellular immunotherapy

Cancer Research

Volumn 68, Issue 10, 2008, Pages 3899-3906

  Hähnel, Patricia S ^a   Thaler, Sonja ^b   Antunes, Edite ^c   Huber, Christoph ^b   Theobald, Matthias ^c   Schuler, Martin ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MCL 1; RAPAMYCIN; SERINE PROTEINASE INHIBITOR; SHORT HAIRPIN RNA; TAMOXIFEN; MAMMALIAN TARGET OF RAPAMYCIN; MCL1 PROTEIN; PROTEIN KINASE; TUMOR PROTEIN;

ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENE TARGETING; GROWTH REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; COCULTURE; ENZYMOLOGY; GENE EXPRESSION REGULATION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MOUSE; MOUSE MUTANT; NEOPLASM; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; MICE; MICE, SCID; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 45549086241     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6286     Document Type: Article

References (31)

1. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004;432:307-15.
2. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003;22:7414-30.
3. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004;305:200-5.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
5. Sawyers C. Targeted cancer therapy. Nature 2004;432:294-7.
6. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-83.
7. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005;115:2618-24.
8. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6:184-92.
9. Manning BD, Cantley LC. AKT/PKB Signaling: navigating downstream. Cell 2007;129:1261-74.
10. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 1991;173:1007-15.
11. Huber C, Bobek N, Kuball J, et al. Inhibitors of apoptosis confer resistance to tumour suppression by adoptively transplanted cytotoxic T lymphocytes in vitro and in vivo. Cell Death Differ 2005;12:317-25.
12. Lee C, Kim JS, Waldman T. PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells. Cancer Res 2004;64:6906-14.
13. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997;185:833-41.
14. Drexler I, Antunes Ferreira E, Schmitz M, et al. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res 1999;59:4955-63.
15. Kagi D, Ledermann B, Burki K, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994;369:31-7.
16. Kohn AD, Barthel A, Kovacina KS, et al. Construction and characterization of a conditionally active version of the serine/threonine kinase Akt. J Biol Chem 1998;273:11937-43.
17. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001;411:385-9.
18. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004;4:371-80.
19. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:7455-64.
20. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004;305:626-9.
21. Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not bax or bak. Science 2007;315:856-9.
22. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2family proteins induces regression of solid tumours. Nature 2005;435:677-81.
23. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-99.
24. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375-88.
25. Wesarg E, Hoffarth S, Wiewrodt R, et al. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer 2007;121:2387-94.
26. Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005;121:1085-95.
27. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006;21:749-60.
28. Wendel H-G, de Stachina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-7.
29. Fox CJ, Hammerman PS, Thompson CB. The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 2005;201:259-66.
30. Smyth MS, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci U S A 1998;95:7024-9.
31. Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000;26:397-404.